Abstract

IntroductionAdherence to antiretroviral therapy (ART) is essential to reduce HIV‐related morbidity and mortality as well as the risk of virological failure and HIV transmission. We determined the trends in ART adherence during the periods of therapeutic advances, wider use of ART and greater attention to ART adherence. To understand the general trends in medication adherence, we compared ART adherence with medications for other common chronic conditions.MethodsA retrospective cohort study using Medicaid claims between 2001 and 2012 from 14 US states with the highest HIV prevalence. Medicaid is the largest source of care for HIV patients in the US. We identified Medicaid beneficiaries with HIV who initiated ART between 2001 and 2010 (n=23,343). Comparison groups included (1) HIV‐ persons who initiated a statin, angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB), or metformin and (2) HIV+ persons who initiated these control medications while on and not on ART. We estimated adjusted odds of >90% medication implementation during the two years following initiation.ResultsThe proportion of HIV+ persons with >90% ART implementation increased from 33.5% in those who initiated in 2001 to 46.4% in 2005 and 52.4% in 2010. ART initiators in 2007 to 2010 had 53% increased odds of >90% implementation compared to those in 2001 to 2003 (adjusted OR 1.53, 99% CI: 1.34 to 1.75). Older age, male, White race, newer ART regimens and absence of substance use indicators were also associated with increased odds of >90% ART implementation. No or minimal improvements were found in the implementation of control medications in HIV‐ persons. For HIV‐ persons, the adjusted ORs comparing 2007–2010 to 2001–2003 were 1.06, 1.01 and 1.19 for statins, ACEI/ARB, metformin respectively. HIV+ persons who were on ART had, on average, 15.0 (SD: 4.2) and 16.1 (SD: 3.4) percentage points higher >90% implementation rates of concurrent statins, ACEI/ARB or metformin compared to HIV‐ persons and HIV+ persons who were not on ART respectively.ConclusionsAdherence to ART substantially improved between 2001 and 2012. Nevertheless, the absolute rates of >90% implementation were low for all groups examined. Substantial disparities by age, sex and race were present, drawing attention to the need to continue to enhance medication adherence. Further studies are required to examine whether these trends and disparities persist in the most recent period.

Highlights

  • Adherence to antiretroviral therapy (ART) is essential to reduce HIV-related morbidity and mortality as well as the risk of virological failure and HIV transmission

  • We identified three groups of patients: HIV+ persons who initiated ART (Group A); HIV- persons who initiated a statin, ACEI/ARB or metformin (Group B); and HIV+ persons who initiated statin, ACEI/ARB or metformin (Group C) between 2001 and 2010 in the Medicaid fee-for-service system

  • 20.0 01 02 03 04 05 06 07 08 09 10 Initiation year with lower pill burden and regimens that included integrase inhibitors. The characteristics of those who initiated statin, ACEI/ARB or metformin are described for HIV- (Group B, Table 2) and HIV+ persons (Group C, Table S1)

Read more

Summary

| INTRODUCTION

The management of HIV infection has changed substantially in the past three decades with the introduction of novel antiretroviral therapy (ART) with improved tolerability and convenience. For patients who can maintain adequate levels of adherence to these effective treatments, HIV infection can be transformed into a manageable chronic condition [3-5]. Many patients with asymptomatic chronic conditions, such as early stage HIV infection, have difficulty adhering to their recommended medication regimens [6]. Medication adherence consists of three phases: initiation, persistence and implementation [10]. Persistence refers to continuous treatment with a prescribed medication, whereas implementation refers to the extent to which a patient follows a prescribed dosing regimen while remaining on treatment [10]. We reported improved persistence with ART among HIV+ persons with Medicaid between 2001 and 2010 [11]. We determined trends in ART implementation in a large population-based cohort of US Medicaid beneficiaries with HIV. To understand the contextual factors that may have influenced secular trends in medication implementation, we compared ART implementation among HIV+ persons with the implementation of control medications (statins, angiotensin-converting enzyme inhibitor (ACEIs) or angiotensin receptor blocker (ARBs) or metformin) among HIV+ and HIV-negative (HIV-) persons

| METHODS
| RESULTS
Findings
| DISCUSSION
| CONCLUSIONS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call